Journal
CLINICAL CANCER RESEARCH
Volume 29, Issue 14, Pages 2570-2572Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-23-0737
Keywords
-
Categories
Ask authors/readers for more resources
A new designing strategy has discovered a bispecific therapeutic antibody co-targeting EPHA2 and EGFR, which effectively inhibits tumor cell growth in various preclinical cancer models. This antibody provides new tools to impair acquired resistance to EGFR-directed therapies or co-target EPHA2 and EGFR in human tumors.
Therapeutic antibodies selectively targeting EPHA2 with or without co-targeting another receptor tyrosine kinase have been limited to date. By integrating state-of-art proteogenomic, ex vivo models, and short hairpin RNA screening approaches, a new designing strategy has now discovered a bispecific therapeutic antibody co-targeting EPHA2 and EGFR - which effectively inhibits tumor cell growth in various preclinical cancer models. This new antibody provides new tools to impair the acquired resistance to EGFRdirected therapies or co-target EPHA2 and EGFR in human tumor.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available